Michael J Lyerly1, Kelly Bartlett1, Karen C Albright1. 1. Department of Neurology (M.J.L.), University of Alabama at Birmingham; Center for Global Health and Translational Science (K.B., K.C.A.), SUNY Upstate Medical University; and Department of Neurology (K.C.A.), SUNY Upstate Medical University, Syracuse, NY.
Abstract
PURPOSE OF REVIEW: CYP2C19 is the primary enzyme involved in the activation of clopidogrel, an antiplatelet agent used for secondary stroke prevention. An individual's CYP2C19 alleles are used to understand their CYP2C19-clopidogrel metabolizer phenotype. Single nucleotide polymorphisms of the CYP2C19 gene result in altered metabolism of this prodrug. RECENT FINDINGS: Three ischemic stroke cases were treated with clopidogrel. Despite confirming adequate drug exposure, medication adherence, and ruling out drug-drug interactions, all had recurrent ischemic stroke. Each case had a CYP2C19 *2/*17 genotype, categorizing them as intermediate clopidogrel metabolizers. Even with the gain-of-function allele, the loss-of-function allele resulted in lack of prodrug activation, leading to decreased efficacy in platelet inhibition. SUMMARY: These cases illustrate the importance of a thoughtful approach to secondary stroke prevention and demonstrate the utility of pharmacogenomic testing in clopidogrel hyporesponders. Recognition of the importance of CYP2C19 genotyping has the potential to enable better selection of appropriate secondary prevention strategies.
PURPOSE OF REVIEW: CYP2C19 is the primary enzyme involved in the activation of clopidogrel, an antiplatelet agent used for secondary stroke prevention. An individual's CYP2C19 alleles are used to understand their CYP2C19-clopidogrel metabolizer phenotype. Single nucleotide polymorphisms of the CYP2C19 gene result in altered metabolism of this prodrug. RECENT FINDINGS: Three ischemic stroke cases were treated with clopidogrel. Despite confirming adequate drug exposure, medication adherence, and ruling out drug-drug interactions, all had recurrent ischemic stroke. Each case had a CYP2C19 *2/*17 genotype, categorizing them as intermediate clopidogrel metabolizers. Even with the gain-of-function allele, the loss-of-function allele resulted in lack of prodrug activation, leading to decreased efficacy in platelet inhibition. SUMMARY: These cases illustrate the importance of a thoughtful approach to secondary stroke prevention and demonstrate the utility of pharmacogenomic testing in clopidogrel hyporesponders. Recognition of the importance of CYP2C19 genotyping has the potential to enable better selection of appropriate secondary prevention strategies.
Authors: Kevin P Bliden; Udaya S Tantry; Robert F Storey; Young-Hoon Jeong; Martin Gesheff; Cheryl Wei; Paul A Gurbel Journal: Am Heart J Date: 2011-06-12 Impact factor: 4.749
Authors: Walter N Kernan; Bruce Ovbiagele; Henry R Black; Dawn M Bravata; Marc I Chimowitz; Michael D Ezekowitz; Margaret C Fang; Marc Fisher; Karen L Furie; Donald V Heck; S Claiborne Clay Johnston; Scott E Kasner; Steven J Kittner; Pamela H Mitchell; Michael W Rich; DeJuran Richardson; Lee H Schwamm; John A Wilson Journal: Stroke Date: 2014-05-01 Impact factor: 7.914
Authors: Jessica L Mega; Willibald Hochholzer; Andrew L Frelinger; Michael J Kluk; Dominick J Angiolillo; Dean J Kereiakes; Steven Isserman; William J Rogers; Christian T Ruff; Charles Contant; Michael J Pencina; Benjamin M Scirica; Janina A Longtine; Alan D Michelson; Marc S Sabatine Journal: JAMA Date: 2011-11-16 Impact factor: 56.272
Authors: Matthew J Price; Peter B Berger; Paul S Teirstein; Jean-François Tanguay; Dominick J Angiolillo; Douglas Spriggs; Sanjeev Puri; Mark Robbins; Kirk N Garratt; Olivier F Bertrand; Michael E Stillabower; Michael E Stillablower; Joseph R Aragon; David E Kandzari; Curtiss T Stinis; Michael S Lee; Steven V Manoukian; Christopher P Cannon; Nicholas J Schork; Eric J Topol Journal: JAMA Date: 2011-03-16 Impact factor: 56.272
Authors: D Sibbing; D Gebhard; W Koch; S Braun; J Stegherr; T Morath; N Von Beckerath; J Mehilli; A Schömig; T Schuster; A Kastrati Journal: J Thromb Haemost Date: 2010-05-21 Impact factor: 5.824
Authors: Laurent Bonello; Udaya S Tantry; Rossella Marcucci; Ruediger Blindt; Dominick J Angiolillo; Richard Becker; Deepak L Bhatt; Marco Cattaneo; Jean Philippe Collet; Thomas Cuisset; Christian Gachet; Gilles Montalescot; Lisa K Jennings; Dean Kereiakes; Dirk Sibbing; Dietmar Trenk; Jochem W Van Werkum; Franck Paganelli; Matthew J Price; Ron Waksman; Paul A Gurbel Journal: J Am Coll Cardiol Date: 2010-09-14 Impact factor: 24.094
Authors: Jessica L Mega; Sandra L Close; Stephen D Wiviott; Lei Shen; Richard D Hockett; John T Brandt; Joseph R Walker; Elliott M Antman; William Macias; Eugene Braunwald; Marc S Sabatine Journal: N Engl J Med Date: 2008-12-22 Impact factor: 91.245
Authors: S A Scott; K Sangkuhl; C M Stein; J-S Hulot; J L Mega; D M Roden; T E Klein; M S Sabatine; J A Johnson; A R Shuldiner Journal: Clin Pharmacol Ther Date: 2013-05-22 Impact factor: 6.875